Characteristics of Study Cohort at Baseline (n = 80)
| Characteristic | Total or median ± IQR |
| Age (y) | 60.9 ± 15.9 |
| Sex | |
| Male | 58 (73%) |
| Female | 22 (27%) |
| Baseline tumor marker level | |
| Carcinoembryonic antigen (ng/mL) | 129.0 ± 526.0 |
| Cancer antigen 19-9 (U/mL) | 85.6 ± 359.0 |
| Hepatic tumor burden > 25% | 23 (29%) |
| Extrahepatic metastasis | 29 (36%) |
| Location of extrahepatic metastasis | |
| Lymph node | 12 (15%) |
| Lung | 12 (15%) |
| Other | 3 (4%) |
| Multiple | 2 (3%) |
| Radioactivity delivered (GBq) | 1.8 ± 0.5 |
| Time between initial diagnosis and radioembolization (wk) | 118 ± 87 |
| Pretreatment | |
| Surgery | |
| Hemihepatectomy | 8 (10%) |
| Partial liver resection | 19 (24%) |
| Chemotherapies | |
| FOLFOX | 59 (74%) |
| FOLFIRI | 67 (84%) |
| Anti-VEGF/EGFR mAb | 65 (81%) |
| Other | 31 (39%) |
| Local therapy | 18 (23%) |
| Baseline PET parameters (mean of 3 lesions) | |
| Metabolic volume (cm3) | 24.4 ± 47.8 |
| Total lesion glycolysis (g) | 186.9 ± 484.3 |
| SUVpeak (g/cm3) | 9.8 ± 4.7 |
| SUVmax (g/cm3) | 11.5 ± 6.3 |
IQR = interquartile range; FOLFOX = folinic acid, fluorouracil, and oxaliplatin; FOLFIRI = folinic acid, fluorouracil, and irinotecan; VEGF = vascular endothelial growth factor; EGFR = epidermal growth factor receptor; mAb = monoclonal antibody.